Open AccessBendamustine-induced nephrogenic diabetes insipidus – A case report
Author(s) -
Audrey Desjardins,
Viviane Le-Nguyen,
Léa Turgeon-Mallette,
Chloé Vo,
Jean Jean-Samuel Boudreault,
Julien Rioux,
Xuping Feng,
Amélie Veilleux
Publication year - 2021
Publication title -
journal of oncology pharmacy practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.548
H-Index - 34
eISSN - 1477-092X
pISSN - 1078-1552
DOI - 10.1177/10781552211013878
Subject(s) - medicine , bendamustine , salvage therapy , etoposide , diabetes insipidus , nephrogenic diabetes insipidus , rituximab , chemoimmunotherapy , surgery , oncology , chemotherapy , lymphoma
In patients with relapsed or refractory lymphoma, high-dose chemoimmunotherapy with subsequent autologous hematopoietic cell transplantation (HCT) is a standard of care. Bendamustine, an alkylating agent, is used in the BeEAM (bendamustine, etoposide, cytarabine, melphalan) protocol for conditioning therapy before autologous HCT in patients with relapsed or refractory lymphoma who are eligible for transplant. There is no consensus regarding an optimal salvage regimen and the approach varies according to toxicity.Case report We present a case of partial nephrogenic diabetes insipidus after receiving bendamustine, as part of the BeEAM protocol. Management and outcome: The patient was managed with parenteral fluid administration and intranasal desmopressin before the condition resolved on its own.Discussion We summarize published reports of bendamustine-induced diabetes insipidus.